Clinical Trials on Human Immunodeficiency Virus Type 1 (HIV-1) in Finland

Total 187 results

GlaxoSmithKline

Completed

Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients

HIV Infection | HIV-1 Infection | Infection, Human Immunodeficiency Virus I

Netherlands, Finland, Ireland, Portugal, Switzerland
Janssen R&D Ireland

Completed

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Human Immunodeficiency Virus Type 1

United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
Brown University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Active, not recruiting

Game Plan for PrEP

Alcohol; Harmful Use | Human Immunodeficiency Virus Exposure

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

Infection, Human Immunodeficiency Virus

United States
Riitta Veijola
Turku University Hospital; Juvenile Diabetes Research Foundation; University... and other collaborators

Recruiting

Type 1 Diabetes Prediction and Prevention (DIPP) Study (DIPP)

Type 1 Diabetes Mellitus

Finland
Gilead Sciences

Completed

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

HIV Infections | Acquired Immunodeficiency Syndrome | HIV-1

United States, Canada
Brown University
The Miriam Hospital; National Institute of General Medical Sciences (NIGMS)

Recruiting

Acute Neural and Immune Effects of Alcohol in People Living With HIV Infection

Alcohol Drinking | HIV-1-infection

United States
Marjukka Kolehmainen
Kuopio University Hospital; Raisio Plc

Completed

Plant Stanols and Type 1 Diabetes

Type 1 Diabetes

Finland
Helsinki University Central Hospital
Medtronic International Trading Sarl

Recruiting

Glycemic Outcomes and Safety With Minimed 780G System in Children With Type 1 Diabetes Aged 2-6 Years

Type 1 Diabetes

Finland
Central Finland Hospital District
University of Jyvaskyla; Finnish Diabetes Association

Completed

Acceptance and Value Based Methods in Increasing Wellbeing of Adolescents With Type 1 Diabetes

Diabetes

Finland
University of Turku
Oulu University Hospital; University of Helsinki; Tampere University

Unknown

Intranasal Insulin for Prevention of Type 1 Diabetes

Type 1 Diabetes

Finland
GlaxoSmithKline

Completed

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

HIV Infection | Infection, Human Immunodeficiency Virus

United States, Belgium, France, Germany, Spain, Canada, Italy, Portugal, Romania, Austria, Switzerland, Poland, Latvia, Luxembourg
Brown University
National Center for Complementary and Integrative Health (NCCIH)

Recruiting

Developing an Online Mindfulness-based Intervention to Reduce Minority Stress and HIV Risk Among Young Adult MSM - Aim 3 (MBQR)

Hiv | Mental Health Wellness 1 | Minority Stress

United States
ViiV Healthcare

Terminated

GW873140 In Combination With Combivir In HIV Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, France, Canada, Germany, Italy, Belgium, United Kingdom, Portugal, Spain
ViiV Healthcare
GlaxoSmithKline

Completed

Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Canada, Puerto Rico
University of Oulu
Turku University Hospital; Oulu University Hospital; Tampere University Hospital

Enrolling by invitation

Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults

Type 1 Diabetes

Finland
ViiV Healthcare
GlaxoSmithKline

Completed

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Canada
Turku University Hospital
Academy of Finland

Completed

Glucose-stimulated Pancreatic Islet and Intestinal Blood Flow in Healthy Subjects and in Type 1 Diabetes (ISLET-PET)

Type 1 Diabetes

Finland
Brown University
National Center for Complementary and Integrative Health (NCCIH)

Active, not recruiting

Developing an Online Mindfulness-based Intervention to Reduce Minority Stress and HIV Risk Among Young Adult MSM

HIV | Mental Health Wellness 1 | Minority Stress

United States
Rhode Island Hospital
Virtually Better, Inc.

Completed

Digital Star: HIV Prevention for Youth in Mental Health Treatment (DSTAR)

Mental Health | Human Immunodeficiency Virus

United States
University of Helsinki
Novo Nordisk A/S; Juvenile Diabetes Research Foundation; European Union; Academy... and other collaborators

Completed

Nutritional Prevention Pilot Trial for Type 1 Diabetes (MIP)

Type 1 Diabetes Mellitus

Finland
Janssen Research & Development, LLC

Completed

A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes

Pre-Symptomatic Type 1 Diabetes

United States, Finland, Sweden
ViiV Healthcare
GlaxoSmithKline

Completed

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects (FLAMINGO)

Infection, Human Immunodeficiency Virus

Spain, France, Germany, United States, Italy, Romania, Russian Federation, Switzerland, Puerto Rico
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. (VIKING-3)

Infection, Human Immunodeficiency Virus

United States, Spain, France, Canada, Portugal, Italy, Belgium
University of Oulu
Turku University Hospital; Oulu University Hospital; Tampere University Hospital and other collaborators

Completed

Incretin-based Therapy in Late Preclinical Type 1 Diabetes

Type 1 Diabetes

Finland, Sweden
University of Oulu
Turku University Hospital; Oulu University Hospital; Tampere University Hospital and other collaborators

Completed

Incretin-based Therapy in Early Diagnosed Type 1 Diabetes

Type 1 Diabetes

Finland, Sweden
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Australia, Canada, Belgium, Denmark, Netherlands, United Kingdom, France, Italy, Romania
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

HIV Infections | Infection, Human Immunodeficiency Virus

Taiwan, France, Germany, Belgium, United States, Canada, Netherlands, Spain, Korea, Republic of, Italy, Australia, United Kingdom, Russian Federation, Portugal, Argentina, South Africa, Romania, Mexico
National Institute of Diabetes and Digestive and...
National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaborators

Active, not recruiting

TEDDY - The Environmental Determinants of Diabetes in the Young

Type 1 Diabetes Mellitus

United States, Finland, Germany, Sweden
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection (MINMON)

Liver Diseases | Hepatitis C | HIV-1-infection

United States, Uganda, Brazil, Puerto Rico, South Africa, Thailand
Medtronic Diabetes

Active, not recruiting

Evaluation of the MiniMed 780 System in Paediatric Subjects (LENNY)

Diabetes type1 | Children, Only

Italy, United Kingdom, Finland, Slovenia
Gilead Sciences

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

HIV-1-infection

United States, Spain, France, Taiwan, Japan, Thailand, Dominican Republic, Germany, Canada, Italy, South Africa
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults (SAILING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Netherlands, Spain, Taiwan, Australia, Belgium, Russian Federation, Canada, United Kingdom, Mexico, Italy, South Africa, Romania, Argentina, Hungary, Poland, Chile, Greece, Brazil
ViiV Healthcare
Pfizer

Terminated

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1 (MODERN)

HIV-1

United States, Netherlands, Spain, Puerto Rico, Canada, Australia, Germany, Sweden, Poland, Portugal, Switzerland, France, Denmark, Italy, Belgium, United Kingdom, Hungary, Austria, Finland
Tibotec Pharmaceuticals, Ireland

Completed

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

HIV-1

United States, Belgium, Germany, Taiwan, Spain, Mexico, Turkey, Canada, Netherlands, Denmark, Greece, Sweden, Korea, Republic of, Russian Federation, Puerto Rico, Luxembourg
University of Cambridge
Juvenile Diabetes Research Foundation; The Leona M. and Harry B. Helmsley Charitable... and other collaborators

Unknown

An Innovative Approach Towards Understanding and Arresting Type 1 Diabetes (INNODIA) (INNODIA)

Type 1 Diabetes Mellitus

Austria, Italy, Finland, Denmark, Germany, Belgium, United Kingdom, France, Luxembourg, Norway, Poland, Slovenia, Sweden
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Hepatitis C | Human Immunodeficiency Virus

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery

HIV-1 Infection

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir

HIV-1 Infection

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults

HIV-1 Infections

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

HIV-1 Infection

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

HIV-1 Infection

United States, Peru, Puerto Rico, Brazil, Botswana, Kenya, South Africa, Thailand
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Rifaximin as a Modulator of Microbial Translocation and Immune Activation

HIV-1 Infection

United States, Puerto Rico
University of Helsinki

Active, not recruiting

Newborn Screening for Genetic Susceptibility to Type 1 Diabetes and Celiac Disease and Prospective Follow-up Study (BABYSCREEN)

Type1diabetes | Celiac Disease

Finland
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

HIV-1 Infection

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART

HIV-1 Infection

United States, Puerto Rico
Diamyd Therapeutics AB

Terminated

A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)

Type 1 Diabetes Mellitus

France, Germany, Finland, Italy, Netherlands, Slovenia, Spain, Sweden, United Kingdom
Rhode Island Hospital

Recruiting

Combined Injectable Treatment for HIV and OUD (CHOICE)

Opioid Use Disorder | Human Immunodeficiency Virus

United States
Andromeda Biotech Ltd.

Completed

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults (DIA-AID2)

Type 1 Diabetes Mellitus

United States, Russian Federation, Israel, Spain, Lithuania, Germany, Austria, Belarus, Canada, Czech Republic, Finland, Hungary, Italy, Poland

Clinical Trials on Human Immunodeficiency Virus Type 1 (HIV-1) in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations